Title: Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults (IPAT Study)
NCT Number: NCT05331144
Status: RECRUITING (estimated completion December 2027)
Phase: Phase 2
Sponsor: University of Texas Southwestern Medical Center
Principal Investigator: Rong Zhang, PhD
Co-Investigators: Wanpen Vongpatanasin, MD; David Zhu, PhD
A 2-arm randomized controlled trial examining whether intensive lowering of systolic BP using FDA-approved antihypertensive medications reduces Alzheimer's Disease pathology in older adults at high risk for memory decline.
| Arm | Intervention | Target |
|---|---|---|
| Intensive Treatment | ARBs (losartan) + CCB (amlodipine) | SBP < 120 mmHg |
| Usual Care | PCP recommendations for BP control | Standard of care |
Elevated systolic blood pressure in midlife is a well-established risk factor for late-onset Alzheimer's disease and vascular cognitive impairment. The IPAT study tests the hypothesis that intensive BP control using FDA-approved medications (ARBs and CCBs) can reduce AD pathology by improving cerebral perfusion and reducing amyloid/tau deposition.
The study builds on: